Plain-English translation of NCT05802394 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a special blood test that looks for cancer DNA can help doctors make better treatment decisions for people with advanced pancreatic cancer. Researchers will take blood samples before and after your initial chemotherapy to see if this test can predict how well your treatment is working. The goal is to understand whether this blood test can guide doctors to change or adjust your therapy before imaging scans show changes.
Currently, doctors rely mainly on CT scans and imaging to decide if treatment is working, but these scans may not detect early signs of remaining cancer. This trial exists to see whether blood tests can catch cancer earlier and help doctors switch treatments sooner, potentially improving outcomes for people with advanced pancreatic cancer.
You likely qualify if…
You likely don't qualify if…
You will have blood drawn before your chemotherapy starts and again at your first imaging scan after chemotherapy. Depending on which group you're assigned to, if the blood test shows cancer DNA is still present but your scans look stable, you'll either switch to a different treatment (MRD-guided group) or continue your current therapy (routine group). The trial will track how you respond and compare these two approaches to see which leads to better outcomes.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China